相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Canagliflozin Prevents Diabetes-Induced Vascular Dysfunction in ApoE-Deficient Mice
Arief Rahadian et al.
JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS (2020)
Inhibition of Acetyl-CoA Carboxylase by Phosphorylation or the Inhibitor ND-654 Suppresses Lipogenesis and Hepatocellular Carcinoma
James S. Lally et al.
CELL METABOLISM (2019)
Effects of Canagliflozin on Heart Failure Outcomes Associated With Preserved and Reduced Ejection Fraction in Type 2 Diabetes Mellitus Results From the CANVAS Program
Gemma A. Figtree et al.
CIRCULATION (2019)
AMP-activated protein kinase: the current landscape for drug development
Gregory R. Steinberg et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
Mendelian Randomization Study of ACLY and Cardiovascular Disease
Brian A. Ference et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Empagliflozin improves primary haemodynamic parameters and attenuates the development of atherosclerosis in high fat diet fed APOE knockout mice
Georgios K. Dimitriadis et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2019)
Low-Dose Methotrexate for the Prevention of Atherosclerotic Events
Paul M. Ridker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Inhibition of Adenosine Monophosphate-Activated Protein Kinase-3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Signaling Leads to Hypercholesterolemia and Promotes Hepatic Steatosis and Insulin Resistance
Kim Loh et al.
HEPATOLOGY COMMUNICATIONS (2019)
AMPK activation protects against diet-induced obesity through Ucp1-independent thermogenesis in subcutaneous white adipose tissue
Alice E. Pollard et al.
NATURE METABOLISM (2019)
SGLT2 inhibition reprograms systemic metabolism via FGF21-dependent and -independent mechanisms
Soravis Osataphan et al.
JCI INSIGHT (2019)
Canagliflozin exerts anti-inflammatory effects by inhibiting intracellular glucose metabolism and promoting autophagy in immune cells
Chenke Xu et al.
BIOCHEMICAL PHARMACOLOGY (2018)
Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program
Karin Radholm et al.
CIRCULATION (2018)
Modulation of matrix metabolism by ATP-citrate lyase in articular chondrocytes
Liang-Yu Chen et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2018)
AMP-Activated Protein Kinase Regulation of the NLRP3 Inflammasome during Aging
Mario D. Cordero et al.
TRENDS IN ENDOCRINOLOGY AND METABOLISM (2018)
Canagliflozin inhibits interleukin-1 beta-stimulated cytokine and chemokine secretion in vascular endothelial cells by AMP-activated protein kinase-dependent and -independent mechanisms
Sarah J. Mancini et al.
SCIENTIFIC REPORTS (2018)
Activation of Liver AMPK with PF-06409577 Corrects NAFLD and Lowers Cholesterol in Rodent and Primate Preclinical Models
Ryan M. Esquejo et al.
EBIOMEDICINE (2018)
Canagliflozin attenuates the progression of atherosclerosis and inflammation process in APOE knockout mice
Narjes Nasiri-Ansari et al.
CARDIOVASCULAR DIABETOLOGY (2018)
A Review of Interleukin-1 in Heart Disease: Where Do We Stand Today?
Yishay Szekely et al.
CARDIOLOGY AND THERAPY (2018)
Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel
Brian A. Ference et al.
EUROPEAN HEART JOURNAL (2017)
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Bruce Neal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
P. M. Ridker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
AMPK as a Therapeutic Target for Treating Metabolic Diseases
Emily A. Day et al.
TRENDS IN ENDOCRINOLOGY AND METABOLISM (2017)
Canagliflozin as an Initial Therapy in Drug-Naive Subjects with Type 2 Diabetes Mellitus: A Potential Involvement of Atherogenic Lipids in its Glycemic Efficacy
Eiji Kutoh et al.
DRUGS IN R&D (2017)
Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis
Kare I. Birkeland et al.
LANCET DIABETES & ENDOCRINOLOGY (2017)
SGLT2 Inhibition by Empagliflozin Promotes Fat Utilization and Browning and Attenuates Inflammation and Insulin Resistance by Polarizing M2 Macrophages in Diet-induced Obese Mice
Liang Xu et al.
EBIOMEDICINE (2017)
Acetyl CoA Carboxylase Inhibition Reduces Hepatic Steatosis but Elevates Plasma Triglycerides in Mice and Humans: A Bedside to Bench Investigation
Chai-Wan Kim et al.
CELL METABOLISM (2017)
Muramyl Dipeptide-Based Postbiotics Mitigate Obesity-Induced Insulin Resistance via IRF4
Joseph F. Cavallari et al.
CELL METABOLISM (2017)
Prevention of Diet-Induced Metabolic Dysregulation, Inflammation, and Atherosclerosis in Ldlr-/- Mice by Treatment With the ATP-Citrate Lyase Inhibitor Bempedoic Acid
Joshua P. Samsoondar et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2017)
AMPK Phosphorylation Modulates Pain by Activation of NLRP3 Inflammasome
Pedro Bullon et al.
ANTIOXIDANTS & REDOX SIGNALING (2016)
Targeting AMP Kinase in Myeloid Cells to Reduce Atherosclerosis
Ajay Chaudhuri et al.
DIABETES (2016)
Salsalate (Salicylate) Uncouples Mitochondria, Improves Glucose Homeostasis, and Reduces Liver Lipids Independent of AMPK-β1
Brennan K. Smith et al.
DIABETES (2016)
Myeloid Deletion of α1AMPK Exacerbates Atherosclerosis in LDL Receptor Knockout (LDLRKO) Mice
Qiang Cao et al.
DIABETES (2016)
The Na+/Glucose Cotransporter Inhibitor Canagliflozin Activates AMPK by Inhibiting Mitochondrial Function and Increasing Cellular AMP Levels
Simon A. Hawley et al.
DIABETES (2016)
Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions A Systematic Review and Meta-analysis
Michael G. Silverman et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
The SGLT-2 Inhibitor Dapagliflozin Has a Therapeutic Effect on Atherosclerosis in Diabetic ApoE-/- Mice
Weiling Leng et al.
MEDIATORS OF INFLAMMATION (2016)
Which is the main molecular target responsible for the cardiovascular benefits in the EMPA-REG OUTCOME trial? A journey through the kidney, the heart and other interesting places
M. Luconi et al.
NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES (2016)
Acetyl-CoA carboxylase inhibition by ND-630 reduces hepatic steatosis, improves insulin sensitivity, and modulates dyslipidemia in rats
Geraldine Harriman et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis
Stephen L. Pinkosky et al.
NATURE COMMUNICATIONS (2016)
Targeting ACLY sensitizes castration-resistant prostate cancer cells to AR antagonism by impinging on an ACLY-AMPK-AR feedback mechanism
Supriya Shah et al.
ONCOTARGET (2016)
The diabetes medication Canagliflozin reduces cancer cell proliferation by inhibiting mitochondrial complex-I supported respiration
Linda A. Villani et al.
MOLECULAR METABOLISM (2016)
IMPROVE-IT and genetics reaffirm the causal role of LDL in Cardiovascular Disease Discussion
Alberico L. Catapano et al.
ATHEROSCLEROSIS (2015)
Metformin and salicylate synergistically activate liver AMPK, inhibit lipogenesis and improve insulin sensitivity
Rebecca J. Ford et al.
BIOCHEMICAL JOURNAL (2015)
Metabolic reprogramming in macrophages and dendritic cells in innate immunity
Beth Kelly et al.
CELL RESEARCH (2015)
Energy Balance After Sodium-Glucose Cotransporter 2 Inhibition
Giulia Ferrannini et al.
DIABETES CARE (2015)
Pharmacological activation of AMPK prevents Drp1-mediated mitochondrial fission and alleviates endoplasmic reticulum stress-associated endothelial dysfunction
Jia Li et al.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2015)
Metabolic Regulation of Immune Responses
Kirthana Ganeshan et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 32 (2014)
An Overview of the New Frontiers in the Treatment of Atherogenic Dyslipidemias
F. H. Rached et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2014)
Fluvastatin Causes NLRP3 Inflammasome-Mediated Adipose Insulin Resistance
Brandyn D. Henriksbo et al.
DIABETES (2014)
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients
Ele Ferrannini et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Evidence for the Role of AMPK in Regulating PGC-1 Alpha Expression and Mitochondrial Proteins in Mouse Epididymal Adipose Tissue
Zhongxiao Wan et al.
OBESITY (2014)
Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors: A Review of Their Basic and Clinical Pharmacology
Sanjay Kalra
DIABETES THERAPY (2014)
Metabolism and Excretion of Canagliflozin in Mice, Rats, Dogs, and Humans
Rao N. V. S. Mamidi et al.
DRUG METABOLISM AND DISPOSITION (2014)
Sodium-Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes A Systematic Review and Meta-analysis
Despoina Vasilakou et al.
ANNALS OF INTERNAL MEDICINE (2013)
AMPKα1 Regulates Macrophage Skewing at the Time of Resolution of Inflammation during Skeletal Muscle Regeneration
Remi Mounier et al.
CELL METABOLISM (2013)
Sex Differences in All-Cause and Cardiovascular Mortality, Hospitalization for Individuals With and Without Diabetes, and Patients With Diabetes Diagnosed Early and Late
Madonna M. Roche et al.
DIABETES CARE (2013)
Canagliflozin Lowers Postprandial Glucose and Insulin by Delaying Intestinal Glucose Absorption in Addition to Increasing Urinary Glucose Excretion Results of a randomized, placebo-controlled study
David Polidori et al.
DIABETES CARE (2013)
Pharmacokinetics and Pharmacodynamics of Canagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor, in Subjects With Type 2 Diabetes Mellitus
Damayanthi Devineni et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2013)
Metabolism of inflammation limited by AMPK and pseudo-starvation
Luke A. J. O'Neill et al.
NATURE (2013)
Single phosphorylation sites in Acc1 and Acc2 regulate lipid homeostasis and the insulin-sensitizing effects of metformin
Morgan D. Fullerton et al.
NATURE MEDICINE (2013)
Malonyl-CoA: the regulator of fatty acid synthesis and oxidation
Daniel W. Foster
JOURNAL OF CLINICAL INVESTIGATION (2012)
The Ancient Drug Salicylate Directly Activates AMP-Activated Protein Kinase
Simon A. Hawley et al.
SCIENCE (2012)
Hematopoietic AMPK β1 reduces mouse adipose tissue macrophage inflammation and insulin resistance in obesity
Sandra Galic et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Progress and challenges in translating the biology of atherosclerosis
Peter Libby et al.
NATURE (2011)
AMPK beta 1 Deletion Reduces Appetite, Preventing Obesity and Hepatic Insulin Resistance
Nicolas Dzamko et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Macrophage α1 AMP-activated Protein Kinase (α1AMPK) Antagonizes Fatty Acid-induced Inflammation through SIRT1
Zhenggang Yang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
The role of IL-1 in the pathogenesis of heart disease
Marcin Bujak et al.
ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS (2009)
Adenosine 5′-Monophosphate-Activated Protein Kinase Promotes Macrophage Polarization to an Anti-Inflammatory Functional Phenotype
Duygu Sag et al.
JOURNAL OF IMMUNOLOGY (2008)
分享论文
